Press Releases

LONDON, May 07, 2026 (GLOBE NEWSWIRE) -- StepStone Group (NASDAQ:STEP), a leading global private markets investment firm, today announced it has joined LSEG's Digital Markets Infrastructure (DMI) platform. Fully integrated within LSEG Workspace, the DMI platform streamlines professional investor access to private funds and utilises distributed ledger technology to support private fund distribution, helping to reduce structural barriers to private markets access for investors. StepStone is among the first private markets managers launching on the DMI platform, with StepStone's evergreen strategies across private equity, private debt and infrastructure available. This collaboration builds

ETF Servicing Solutions Support Launch of Calamos Investments' Strategy for European Investors Northern Trust (NASDAQ:NTRS) today announced it has supported the launch of a new exchange‑traded fund (ETF) on the Waystone ETF ICAV, Waystone's Irish‑domiciled white‑label multi‑manager ETF platform. The launch of the Calamos Autocallable Income UCITS sub fund introduces U.S. asset manager Calamos Investments (Calamos) onto the platform and marks the first autocallable ETF in Europe.1 Calamos is headquartered in Naperville, Illinois, and has $47.2 billion in assets under management (as of 31 March 2026). This derivatives‑based, synthetic investment strategy seeks to deliver returns that re

The Kraft Heinz Company ("Kraft Heinz") (NASDAQ:KHC) announced today that Kraft Heinz Foods Company, its 100% owned subsidiary (the "Issuer"), has commenced an offer to purchase for cash (the "Tender Offer") up to the maximum combined aggregate purchase price of $1,100,000,000, excluding accrued and unpaid interest (the "Maximum Tender Amount"), of its outstanding 4.375% Senior Notes due June 2046 and its 4.875% Senior Notes due October 2049 (collectively, the "Notes" and, each, a "Series" of Notes), from each registered holder of the Notes (the "Holders"). Subject to the Maximum Tender Amount, the amount of a Series of Notes that is purchased in the Tender Offer will be based on the Accept

Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ:NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excell

Advancing sustainable, high-quality naturals through end‑to‑end stewardship LMR Naturals by IFF — a global leader in natural ingredients for perfumery, cosmetics and flavors — will debut its latest innovations at the International Exhibition of Raw Materials for Perfumery (SIMPPAR), May 26–27 in Grasse. During the industry event, IFF will unveil new additions to its LMR Hearts collection, highlighting its naturals expertise and pioneering science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506065669/en/Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. "Responsible innovation h

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE:APO) today announced that Apollo-managed funds (the "Apollo Funds") have completed the previously announced acquisition of a majority stake in Prosol Group ("Prosol" or the "Company"), the multi-specialist in fresh food businesses and food retail in France, from Ardian, a global private investment firm. Prosol's existing minority shareholders and management team have reinvested alongside the Apollo Funds. Founded in 1992, Prosol has differentiated itself by building a proprietary, vertically integrated supply chain, sourcing fresh, quality products resulting in a highly loyal and fast-growing customer base. Prosol operates and/or sup

Reinventing the ‘WTA Player Zone' experience for athletes through technology, data, and AI Accenture (NYSE:ACN) and the WTA (Women's Tennis Association) have announced a new, multi-year partnership, focused on enhancing the player experience and helping shape the future of women's tennis. The collaboration will fuse Accenture's leadership in technology and AI enablement with the WTA's commitment to excellence as a modern, athlete-first governing body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506788348/en/Mauro Macchi, Accenture EMEA CEO, alongside Marina Storti, CEO WTA Ventures at the 2026 Italian Open, following par

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A. ("Angelini Pharma"), an international pharmaceutica

Shell plc Shell announces commencement of a share buyback programme  May 7, 2026 Shell plc (the ‘Company') today announces the commencement of a $3.0 billion share buyback programme covering an aggregate contract term of approximately three months (the ‘programme'). The purpose of the programme is to reduce the issued share capital of the Company. All shares repurchased as part of the programme will be cancelled. It is intended that, subject to market conditions, the programme will be completed prior to the Company's Q2 2026 results announcement1. The Company has entered into an arrangement with a single broker consisting of one, non-discretionary contract, to enable the purchase of ordi

London, May 7, 2026 − The Board of Shell plc (the "Company") (XLON: SHEL, NYSE:SHEL, XAMS: SHELL) today announced an interim dividend in respect of the first quarter of 2026 of US$ 0.3906 per ordinary share. Details relating to the first quarter 2026 interim dividend Per ordinary share(GB00BP6MXD84) Q1 2026Shell Shares (US$)0.3906 Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling. An alternative ‘Electronic Election Entitlement' (‘EEE') process is available in CREST for dividends with options elections. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their divid

London, May 7, 2026  "Shell delivered strong results enabled by our relentless focus on operational performance in a quarter marked by unprecedented disruption in global energy markets. The safety of our people remains our priority as we work closely with governments and customers to address their energy needs. Last week we announced the acquisition of ARC Resources, accelerating our strategy by adding complementary, high-quality, low-cost liquids and gas assets that we believe will deliver value for decades to come. Today, consistent with our value driven capital allocation philosophy, we are rebalancing our shareholder distributions, with a $3 billion share buyback programme for the nex

                 SHELL PLC1st QUARTER 2026 UNAUDITED RESULTS                       SUMMARY OF UNAUDITED RESULTSQuarters$ million Q1 2026Q4 2025Q1 2025 Reference5,6944,1344,780Income attributable to Shell plc shareholders 6,9153,2565,577Adjusted EarningsA.17,74112,79915,250Adjusted EBITDAA.6,0629,4389,281Cash flow from operating activities (3,136)(5,190)(3,959)Cash flow from investing activities 2,9274,2495,322Free cash flowG.4,2026,0154,175Cash capital expenditureC.8,7169,5598,575Operating expensesF.8,5859,4368,453Underlying operating expensesF.9.9%9.4%10.4%ROACED.75,64575,64376,511Total debtE.52,60645,68741,521Net debtE.23.2%20.7%18.7%GearingE.2,7522,8592,838Oil and gas production available

ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV (NYSE:CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO)) ("CMBT", "CMB.TECH" or "the Company") will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the "Investor Relations" page of the website. The presentation, recording & transcript will also be available on this page. Webcast Information Event Type: Video conference call with slide presentationEvent Date:19 May 2026Event Time:8 a

AdvanSix (NYSE:ASIX), a vertically integrated chemistry company serving diverse end markets, today announced it has entered into a process design and licensing agreement to assess expansion of its integrated ammonia platform at its Hopewell, Virginia site to enable the domestic manufacturing of Diesel Exhaust Fluid (DEF), a critical emissions-control product used across on-and-off highway diesel applications. DEF is an additive for reducing NOx emissions from diesel engines, with strong and growing demand driven primarily by Class 8 vehicle usage in the Mid-Atlantic and Northeast of the United States. The AdvanSix Hopewell site provides a strong foundation for this expansion, as it alread

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA. Across multiple presentations, the Company and its collaborators will share interim outcomes of a long-term extension study for leniolisib in pediatric patients aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The presentations will also include clinical data from expanded access use of leniolisib to treat immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and CVID-like disorders, as

Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that it has decided to initiate a share buy-back program (the "Program") in accordance with company announcement no. 13 / 2026. This regulatory update summarizes the execution framework of the Program, to which the following terms apply: The Program will be implemented in accordance with Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation

First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. marketsJoenja® revenue was US$14.1 million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentumReaffirmed 2026 total revenue guidance of US$405 - US$425 million (8% - 13% growth)Generated positive net cash flow from operations of US$2.0 million in the quarterJoenja® approved in Japan and received positive CHMP opinion for APDSResubmitted pediatric sNDA to the FDA for Jo

Materialise transfers eyewear business to its management team Regulated information1 Materialise NV ((Euronext &, NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the first quarter ended March 31, 2026. Additionally, Materialise announced the transfer of its eyewear business to the eyewear management team. Highlights – First Quarter 2026 Total revenue was stable at 66,276 kEUR for the first quarter of 2026 compared to 66,379 kEUR for the corresponding 2025 period. Gross profit as a percentage of revenue for the first quarter of 2026 increased to 57.2%

$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative ("seronegative") gMG PDUFA is May 10, 2026 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 7, 2026 7:00AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2026 results and provided a business update. "argenx continues to deliver meaningful impact for patients, reflected by our 17th consecutive quarter of VYVGART growth," said Karen Massey, Chief Executive Officer of argen